Jason B. Litten

740 total citations
21 papers, 537 citations indexed

About

Jason B. Litten is a scholar working on Oncology, Molecular Biology and Hepatology. According to data from OpenAlex, Jason B. Litten has authored 21 papers receiving a total of 537 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Molecular Biology and 5 papers in Hepatology. Recurrent topics in Jason B. Litten's work include Fibroblast Growth Factor Research (4 papers), CAR-T cell therapy research (4 papers) and Hepatocellular Carcinoma Treatment and Prognosis (4 papers). Jason B. Litten is often cited by papers focused on Fibroblast Growth Factor Research (4 papers), CAR-T cell therapy research (4 papers) and Hepatocellular Carcinoma Treatment and Prognosis (4 papers). Jason B. Litten collaborates with scholars based in United States, France and Australia. Jason B. Litten's co-authors include Gail E. Tomlinson, Gustavo Grampp, Filippo de Braud, Bárbara Adamo, Josep Tabernero, Andrew R. Allen, Rastilav Bahleda, R. Cereda, Maurizio D’Incalci and Frédéric Dubois and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Jason B. Litten

20 papers receiving 518 citations

Peers

Countries citing papers authored by Jason B. Litten

Since Specialization

Citations

This map shows the geographic impact of Jason B. Litten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason B. Litten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason B. Litten more than expected).

Fields of papers citing papers by Jason B. Litten

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason B. Litten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason B. Litten. The network helps show where Jason B. Litten may publish in the future.

Co-authorship network of co-authors of Jason B. Litten

This figure shows the co-authorship network connecting the top 25 collaborators of Jason B. Litten. A scholar is included among the top collaborators of Jason B. Litten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason B. Litten. Jason B. Litten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase 1/2 study to evaluate CHM-2101, an autologous cadherin 17 (CDH17) chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed or refractory gastrointestinal cancers. 2025 ·Journal of Clinical Oncology ·Jennifer R. Eads, Maria Pia Morelli, Daniel J. Olson, Jason B. Litten, Stephanie H. Astrow, Meredith Pelster	0
2	Phase 1b multicenter study to evaluate CHM 1101 in patients with recurrent or progressive glioblastoma. 2023 ·Journal of Clinical Oncology ·Jason B. Litten, Aravind Ramakrishnan, Stephanie H. Astrow, (unknown), (unknown), Behnam Badie	5
3	129 Development of AB-201, a novel allogeneic anti-HER2-specific CAR-NK cell therapy for the treatment of HER2+ tumors 2021 ·Regular and Young Investigator Award Abstracts ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Eun Ji Kim, Eunsol Lee, Jeong‐Min Kim, (unknown), Bokyung Min, (unknown), (unknown), (unknown), Srinivas S. Somanchi, (unknown), Jason B. Litten, Peter Flynn, Heather K. Raymon, Yu Kyeong Hwang	1
4	Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma 2017 ·The Oncologist ·Ghassan K. Abou‐Alfa, Jean‐Frédéric Blanc, Steven A. Miles, Tom M. Ganten, Jörg Trojan, Jonathan Cebon, André Liem, Lara Lipton, (unknown), Benjamin Wu, Michael Bass, Ellen Hollywood, Jennifer Ma, (unknown), Jason B. Litten, Leonard B. Saltz	20
5	PS01.66: Biomarker Stratification of Outcomes of Third-Generation EGFR TKI Therapy in Patients with Previously-Treated Advanced NSCLC 2016 ·Journal of Thoracic Oncology ·Heather A. Wakelee, Jonathan W. Goldman, Shirish M. Gadgeel, David Ross Camidge, Karen L. Reckamp, Sai‐Hong Ignatius Ou, Helena A. Yu, Benjamin Solomon, Stephen V. Liu, M. Pérol, Nicholas Dupuis, (unknown), Chris Karlovich, Mitch Raponi, Sergey Yurasov, Jason B. Litten, Darrin Despain, Jean‐Charles Soria, Lecia V. Sequist, David P. Carbone	1
6	Abstract OT1-1-13: A Phase 2, randomized, open-label, multicenter, safety and efficacy study of oral lucitanib in patients with metastatic breast cancer with alterations in the FGF pathway 2015 ·Cancer Research ·Maysa Abu‐Khalaf, Ingrid A. Mayer, Jason B. Litten, Mitch Raponi, Andrew R. Allen, Lajos Pusztai, Carlos L. Arteaga	1
7	TIGER 1: A randomized, open-label, phase 2/3 study of rociletinib (CO-1686) or erlotinib as first-line treatment for EGFR-mutant non-small cell lung cancer (NSCLC). 2015 ·Journal of Clinical Oncology ·D. Ross Camidge, Juergen Wolf, Jason B. Litten, (unknown), Jeffrey D. Isaacson, Tony Mok	4
8	Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors 2014 ·Annals of Oncology ·J.C. Soria, Filippo de Braud, Rastilav Bahleda, Bárbara Adamo, Fabrice André, (unknown), Angelo Delmonte, R. Cereda, (unknown), Jason B. Litten, Andrew R. Allen, Frédéric Dubois, (unknown), (unknown), Maurizio D’Incalci, Massimo Zucchetti, (unknown), Josep Tabernero	147
9	A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer 2014 ·Gynecologic Oncology ·Ignace Vergote, Russell J. Schilder, Charles H. Pippitt, Shirley Wong, Alan N. Gordon, Sidney Scudder, Frédéric Kridelka, Luc Dirix, Joseph W. Leach, Sumitra Ananda, Nuwan Nanayakkara, (unknown), Michael Bass, Jason B. Litten, (unknown), Robert M. Wenham	15
10	Phase II study of first-line trebananib plus sorafenib in patients with advanced hepatocellular carcinoma (HCC). 2014 ·Journal of Clinical Oncology ·Ghassan K. Abou‐Alfa, Jean‐Frédéric Blanc, Steven A. Miles, Tom M. Ganten, Jörg Trojan, Jonathan Cebon, André Liem, Lara Lipton, (unknown), Benjamin Wu, Jason B. Litten, Leonard B. Saltz	7
11	10LBA Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer 2014 ·European Journal of Cancer ·J.C. Soria, Lecia V. Sequist, (unknown), Heather A. Wakelee, S. Gadgeel, Andreea Varga, Huiqing Yu, Benjamin Solomon, S.-H.I. Ou, V. Papadimitrakopoulou, Geoffrey R. Oxnard, (unknown), Rafał Dziadziuszko, Bo H. Chao, Alexander I. Spira, (unknown), Tarek Mekhail, Shannon Matheny, Jason B. Litten, (unknown)	4
12	A single arm, open-label, phase II study to assess the efficacy of lucitanib in patients with FGFR1-amplified squamous NSCLC (sqNSCLC). 2014 ·Journal of Clinical Oncology ·David R. Spigel, (unknown), Jason B. Litten, Andrew R. Allen, Giuseppe Giaccone, Mark A. Socinski, D. Ross Camidge, Benjamin Besse	4
13	A phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. 2014 ·Journal of Clinical Oncology ·Jean‐Charles Soria, Filippo de Braud, Ratislav Bahleda, Bárbara Adamo, (unknown), (unknown), (unknown), Jeffrey D. Isaacson, Jason B. Litten, Andrew R. Allen, Lindsey Rolfe, Josep Tabernero	8
14	Prolonged Anti-Tumor Activity of Lucitanib in Advanced Thyroid Cancer 2014 ·Annals of Oncology ·(unknown), Rodrigo Dienstmann, Bárbara Adamo, R. Cereda, Jason B. Litten, (unknown), (unknown), (unknown), (unknown), Filippo de Braud, Jean‐Charles Soria, Josep Tabernero	2
15	Pharmacovigilance and biosimilars: considerations, needs and challenges 2013 ·Expert Opinion on Biological Therapy ·Nicole Casadevall, (unknown), (unknown), Peter R. Graze, Jason B. Litten, Bruce Strober, David G. Warnock	49
16	Pharmacokinetics of Irinotecan With and Without Panitumumab Coadministration in Patients With Metastatic Colorectal Cancer 2013 ·Clinical Pharmacology in Drug Development ·Bingbing Yang, Chi‐Yuan Wu, Eric X. Chen, Jeffrey R. Infante, (unknown), Bing Gao, Brian P. Smith, Jason B. Litten, Hagen F. Kennecke	3
17	Comparability and biosimilarity: considerations for the healthcare provider 2012 ·Current Medical Research and Opinion ·(unknown), Jason B. Litten, Gustavo Grampp	77
18	Activated NOTCH2 is Overexpressed in Hepatoblastomas: An Immunohistochemical Study 2011 ·Pediatric and Developmental Pathology ·Jason B. Litten, (unknown), Roger A. Schultz, (unknown), Jessica Comstock, Joshua D. Schiffman, Gail E. Tomlinson, Dinesh Rakheja	20
19	Liver Tumors in Children 2008 ·The Oncologist ·Jason B. Litten, Gail E. Tomlinson	147
20	Acute lymphoblastic leukemia presenting in fulminant hepatic failure 2005 ·Pediatric Blood & Cancer ·Jason B. Litten, Maria M. Rodríguez, (unknown)	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact